Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide in mCRPC
NCT02691975Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Apr 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rezvilutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hengrui. Primary endpoints: Maximum Tolerated Dose at 12 weeks and Radiological Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
rezvilutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02691975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691975.